Can acotinib treat gastric cancer?

Currently, acotinib (Acalabrutinib) is mainly used to treat specific types of leukemia and lymphoma, such as chronic lymphocytic leukemia (CLL), small cell lymphoma (S LL), follicular lymphoma (FL), and diffuse largeB cell lymphoma (DLBCL). Although acotinib has shown good efficacy in targeting these hematological tumors, it has not yet been proven to have a therapeutic effect on gastric cancer.

Gastric cancer is a common malignant tumor of the digestive system, and its treatment is challenging. Conventional treatment options include surgical resection, chemotherapy, radiotherapy and targeted therapy. In the treatment of gastric cancer, targeted therapy usually targets specific molecular targets of gastric cancer cells to inhibit tumor growth and spread.

Currently, acotinib is not widely used to treat gastric cancer. In contrast, targeted therapies for gastric cancer typically include inhibitors of HER2 expression, such as trastuzumab and pertuzumab, as well as inhibitors of HER2 expression. EGFR (epidermal growth factor receptor) inhibitors, such as cetuximab (Cetuximab) and hirodanib (Nimotuzumab).

Although acotinib has shown good efficacy and safety in the treatment of leukemia and lymphoma, its clinical trials in the treatment of gastric cancer have not yet been conducted or have not shown sufficient efficacy. Therefore, if patients suffer from gastric cancer, they should still follow the standard treatment regimen recommended by current clinical guidelines and choose the most appropriate treatment option under the guidance of a doctor.